Pharmacogenetics of pharmacodynamic targets of statin action
https://doi.org/10.24411/2588-0527-2019-10035
Abstract
A scientific review of current data on the effect of the genetic polymorphism of the most studied and proven candidate genome pharmacological targets involved in the lipid-lowering and clinical effect of statins is presented. Such candidate genes as APOE, СЕТР, HMGCR, LDL receptor, LPA, and KIF6 are examined and the results of studies and meta-analyzes confirming their effect on statin efficacy, mainly LDL and HDL levels are shown. Polymorphism of these genes promotes variability of hypolipidemic effect in real clinical practice and has interethnic features. Genotyping by predictive markers of pharmacodynamic effectiveness of statins can represent the basis of personalized medicine.
About the Author
M. V. Leonova
Association of clinical pharmacologists
Russian Federation
Russian Federation
Leonova Marina – DM, professor, Corresponding Member of RAEN, clinical pharmacologist, member of Interregional public organization Association of clinical pharmacologists of Russia. SPIN-code: 3281-7884
Moscow
References
1. Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376:1670–1681. DOI: 10.1016/S0140-6736(10)61350-5
2. Van Ganse E, Laforest L, Alemao E, et al. Lipid-modifucation therapy and attainment in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study. Curr Med Res Opin. 2005;21:1389–1399. DOI: 10.1185/030079905X59139
3. Kim HS, Wu Y, Lin SJ, et al. Current status of cholesterol goal attainment after statin therapy among patients with hypercholesterolemia in Asian countries and region: the Return on Expenditure Achieved for Lipid Therapy in Asia (REALITY-Asia) study. Curr Med Res Opin. 2008; 24(7):19511963. DOI:10.1185/03007990802138731
4. Susekov AV, Zubarevа MYu, Deev AD, et al. Main results Moscow research on statins (Moscow Statin Survey, MSS). Serdtse. 2006;6:324–328. (In Russ).
5. Zineh I. Pharmacogenetics of Response to Statins. Curr Аtheroscler rep. 2007;9(3):187–194.
6. Maggo SD, Kennedy MA, Clark DW. Clinical implications of pharmacogenetic variation on the effects of statins. Drug Saf. 2011;34:1–19. DOI: 0114-5916/11/0001-0001/$49.95/0
7. Duman I. Role of Pharmacogenetics on Response to Statins: A Genotype-based Approach to Statin Therapy Outcome. Journal of Cardiology and Therapy. 2014;1(6):111–120. DOI:10.6051/j.issn.2309-6861.2014.01.35
8. Nieminen T, Kähönen M, Viiri LE, et al. Pharmacogenetics of apolipoprotein E gene during lipid-lowering therapy: lipid levels and prevention of coronary heart disease. Pharmacogenomics. 2008;9:1475–1486. DOI: 10.2217/14622416.9.10.1475
9. Baptista R, Rebelo M, Decq-Mota J, et al. Apolipoprotein E epsilon-4 polymorphism is associated with younger age at referral to a lipidology clinic and a poorer response to lipid-lowering therapy. Lipids Health Dis. 2011;10:48. DOI: 10.1186/1476-511X-10-48
10. Villeneuve S, Brisson D, Marchant NL, Gaudet D. The potential applications of Apolipoprotein E in personalized medicine. Front Aging Neurosci. 2014;6:154. DOI: 10.3389/fnagi.2014.00154
11. Song Y, Stampfer MJ, Liu S. Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann. Intern. Med. 2004;141:137–147. DOI: 10.7326/0003-4819-141-2-200407200-00013
12. Yin YW, Sun QQ, Zhang BB, et al. Association between apolipoprotein E gene polymorphism and the risk of coronary artery disease in Chinese population: evidence from a meta-analysis of 40 studies. PLoS One/ 2013;8:e66924. DOI: 10.1371/journal.pone.0066924
13. Hubacek JA, Vrablik M. Effect of apolipoprotein E polymorphism on statin-induced decreases in plasma lipids and cardiovascular events. Drug Metabol Drug Interact. 2011;26(1):13–20. DOI: 10.1515/DMDI.2011.107
14. Ballantyne CM, Herd JA, Stein EA, et al. Apolipoprotein E genotypes and response of plasma lipids and progressionregression of coronary atherosclerosis to lipid-lowering drug therapy. J Am Coll Cardiol. 2000;36(5):1572–1578. DOI: 10.1016/S0735-1097(00)00918-9
15. Pedro-Botet J, Schaefer EJ, Bakker-Arkema RG, et al. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. Atherosclerosis. 2001;158(1): 183–193.
16. Donnelly LA, Palmer CN, Whitley AL, et al. Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study. Pharmacogenet Genomics. 2008;18:279–287. DOI: 10.1097/FPC.0b013e3282f60aad
17. Mega JL, Morrow DA, Brown A, et al. Identification of Genetic Variants Associated With Response to Statin Therapy. Arterioscler Thromb Vasc Biol. 2009;29:1310–1315. DOI: 10.1161/ATVBAHA.109.188474
18. Thompson JF, Hyde CL, Wood LS, et al. Comprehensive wholegenome and candidate gene analysis for response to statin therapy in the treating to new targets (TNT) cohort. Circ. Cardiovasc. Genet. 2009;2:173–181. DOI: 10.1161/CIRCGENETICS.108.818062
19. Hopewell JC, Parish S, Offer A, et al. Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection study. Eur. Heart J. 2013;34:982–992. DOI: 10.1093/eurheartj/ehs344
20. Maitland-van der Zee AH, Jukema JW, Zwinderman AH, et al. Apolipoprotein-E polymorphism and response to pravastatin in men with coronary artery disease (REGRESS). Acta Cardiol. 2006;61:327–331. DOI: 10.2143/AC.61.3.2014836
21. Maitland-van der Zee AH, Stricker BH, Klungel OH, et al. Adherence to and dosing of beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitors in the general population differs according to apolipoprotein E-genotypes. Pharmacogenetics. 2003;13:219–223. DOI: 10.1097/01.fpc.0000054080.64000.f1
22. Zintzaras E, Kitsios GD, Triposkiadis F, et al. APOE gene polymorphisms and response to statin therapy among APOE genetic variants. Pharmacogenomics J. 2009;9:248–257. DOI: 10.1038/tpj.2009.25
23. Gerdes LU, Gerdes C, Kervinen K, et al. The apolipoprotein ε4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the Scandinavian simvastatin survival study. Circulation. 2000;101(12):1366–1371. DOI: 10.1161/01.CIR.101.12.1366
24. Dergunov AD. Apolipoprotein E genotype as a most significant predictor of lipid response at lipid-lowering therapy: mechanistic and clinical studies. Biomed. Pharmacother. 2011;65:597–603. DOI:10.1016/j.biopha.2011.04.003
25. Ordovas JM. Genetic polymorphisms and activity of cholesterol ester transfer protein (CETP): Should we be measuring them? Clin. Chem. Lab. Med. 2000;38:945–949. DOI: 10.1515/CCLM.2000.139
26. Tsai MY, Johnson C, Kaoc WHL, et al. Cholesteryl ester transfer protein genetic polymorphisms, HDL cholesterol, and subclinical cardiovascular disease in the Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2008;200:359–367. DOI:10.1016/j.atherosclerosis.2007.12.038
27. Cao M, Zhou ZW, Fang BJ, et al. Meta-analysis of cholesteryl ester transfer protein TaqIB polymorphism and risk of myocardial infarction. Medicine (Baltimore). 2014;93(26):e160. DOI: 10.1097/MD.0000000000000160
28. Guo SX, Yao MH, Ding YS, et al. Associations of Cholesteryl Ester Transfer Protein TaqIB Polymorphism with the Composite Ischemic Cardiovascular Disease Risk and HDL-C Concentrations: A Meta-Analysis. Int J Environ Res Public Health. 2016;13(9):882–901. DOI: 10.3390/ijerph13090882
29. van Venrooij FV, Stolk RP, Banga JD, et al. Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes. Diabetes Care. 2003; 26:1216–1223. DOI: 10.2337/diacare.26.4.1216
30. Fiegenbaum M, da Silveira FR, Van der Sand CR, et al. Pharmacogenetic study of apolipoprotein E, cholesteryl ester transfer protein and hepatic lipase genes and simvastatin therapy in Brazilian subjects. Clin Chim Acta. 2005;362:182–188. DOI: 10.1016/j.cccn.2005.06.005
31. Carlquist JF, Muhlestein JB, Horne BD, et al. The cholesteryl ester transfer protein Taq1B gene polymorphism predicts clinical benefit of statin therapy in patients with significant coronary artery disease. Am Heart J. 2003;146(6):1007–1014. DOI: 10.1016/S0002-8703(03)00501-5
32. Li Q, Huang P, He Q-C, et al. Association between the CETP polymorphisms and the risk of Alzheimer’s disease, carotid atherosclerosis, longevity, and the efficacy of statin therapy. Neurobiology of Aging. 2014;35:1513.e13-1513.e23. DOI:10.1016/j.neurobiolaging.2013.12.032
33. McTaggart F, Jones P. Effects of statins on high-density lipoproteins: a potential contribution to cardiovascular benefit. Cardiovasc Drugs Ther. 2008;22(4):321–338. DOI: 10.1007/s10557-008-6113-z
34. Kuivenhoven JA, Jukema JW, Zwinderman AH, et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. The Regression Growth Evaluation Statin Study Group. N Engl J Med. 1998;338(2):86–93. DOI: 10.1056/NEJM199801083380203
35. Regieli JJ, Jukema JW, Grobbee DE, et al. CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction. Eur. Heart J. 2008;29(22):2792–2799. DOI: 10.1093/eurheartj/ehn465
36. Boekholdt SM, Sacks FM, Jukema JW, et al. Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13,677 subjects. Circulation. 2005;111(3):278–287. DOI: 10.1161/01.CIR.0000153341.46271.40
37. Chasman DI, Posada D, Subrahmanyan L, et al. Pharmacogenetic study of statin therapy and cholesterol reduction. JAMA. 2004;291:2821–2827. DOI: 10.1001/jama.291.23.2821
38. Donnelly LA, Doney AS, Dannfald J, et al. A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study. Pharmacogenet Genomics. 2008;18:1021–1026. DOI: 10.1097/FPC.0b013e3283106071
39. Krauss RM, Mangravite LM, Smith JD, et al. Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment. Circulation. 2008;117:1537–1544. DOI: 10.1161/CIRCULATIONAHA.107.708388
40. Polisecki E, Muallem H, Maeda N, et al. Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) Investigatorset al. Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER. Atherosclerosis. 2008;200:109–114. DOI: 10.1016/j.atherosclerosis.2007.12.004
41. Erqou S, Kaptoge S, Perry PL, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302:412–423. DOI: 10.1001/jama.2009.1063
42. Malaguarnera M, Vacante M, Russo C, et al. Lipoprotein(a) in cardiovascular diseases. Biomed. Res. Int. 2013;2013:650989. DOI: 10.1155/2013/650989
43. Deshmukh HA, Colhoun HM, Johnson T, et al. Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a). J. Lipid Res. 2012;53:1000–1011. DOI: 10.1194/jlr.P021113
44. Chasman DI, Giulianini F, MacFadyen J, et al. Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Circ. Cardiovasc. Genet. 2012;5: 257–264. DOI: 10.1161/CIRCGENETICS.111.961144
45. Donnelly LA, van Zuydam NR, Zhou K, et al. Robust association of the LPA locus with low-density lipoprotein cholesterol lowering response to statin treatment in a meta-analysis of 30 467 individuals from both randomized control trials and observational studies and association with coronary artery disease outcome during statin treatment. Pharmacogenet Genomics. 2013;23(10):518–525. DOI: 10.1097/FPC.0b013e3283642fd6
46. Choumerianou DM, Dedoussis GV. Familial hypercholesterolemia and response to statin therapy according to LDLR genetic background. Clin Chem Lab Med. 2005;43:793–801.
47. Assimes TL, Hólm H, Kathiresan S, et al. Lack of association between the Trp719Arg polymorphism in kinesin-like protein-6 and coronary artery disease in 19 case-control studies. J Am Coll Cardiol. 2010;56:1552–1563. DOI: 10.1016/j.jacc.2010.06.022
48. Ruiz-Ramos D, Hernández-Díaz Y, Tovilla-Zárate CA, Juárez-Rojop I, López-Narváez ML, González-Castro TB, Torres-Hernández ME, BañosGonzález MA. The Trp719Arg polymorphism of the KIF6 gene and coronary heart disease risk: systematic review and meta-analysis. Hereditas. 2015;152:3. DOI: 10.1186/s41065-015-0004-7
49. Peng P, Lian J, Huang RS, et al. Meta-analyses of KIF6 Trp719Arg in coronary heart disease and statin therapeutic effect. PLoS One. 2012;7(12):e50126. DOI: 10.1371/journal.pone.0050126
50. Li Y, Iakoubova OA, Shiffman D, et al. KIF6 polymorphism as a predictor of risk of coronary events and of clinical event reduction by statin therapy. Am J Cardiol. 2010;106(7):994–998. DOI: 10.1016/j.amjcard.2010.05.033
51. Leusink M, Onland-Moret NC, de Bakker PIW, et al. Seventeen years of statin pharmacogenetics: a systematic review. Pharmacogenomics. 2016;17(2):163–180. DOI: 10.2217/pgs.15.158
52. Postmus I, Trompet S, Deshmukh HA, et al. Pharmacogenetic metaanalysis of genome-wide association studies of LDL cholesterol response to statins. Nat Commun. 2014;5:5068. DOI: 10.1038/ncomms6068
53. Postmus I, Warren HR, Trompet S, et al. Meta-analysis of genomewide association studies of HDL cholesterol response to statins. J Med Genet. 2016;53(12):835–845. DOI: 10.1136/jmedgenet-2016-103966
Review
For citations:
Leonova M.V. Pharmacogenetics of pharmacodynamic targets of statin action. Pharmacogenetics and Pharmacogenomics. 2019;(1):3-11. (In Russ.) https://doi.org/10.24411/2588-0527-2019-10035
Views:
806
Email this article 
Post a Comment 